Cover Image

Osteoporosis in thalassaemia

Ersi Voskaridou, Maria Dimopoulou, Evangelos Terpos
  • Ersi Voskaridou
    Thalassaemia and Sickle Cell Disease Centre, “Laiko” General Hospital, Athens, Greece | ersi.voskaridou@gmail.com
  • Maria Dimopoulou
    Thalassaemia and Sickle Cell Disease Centre, “Laiko” General Hospital, Athens, Greece
  • Evangelos Terpos
    Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Abstract

Osteoporosis is a prominent cause of morbidity in patients with thalassaemia major (TM) with a complex pathophysiology. Patients with TM and osteoporosis have elevated markers of bone resorption. This increased osteoclast activity seems to be at least partially due to an imbalance in the receptor–activator of nuclear factor-kappa B ligand (RANKL)/osteoprotegerin (OPG) system, which is of great importance for the regulation of osteoclast differentiation and function. Denosumab is a fully human monoclonal antibody that binds to RANKL and thereby inhibits the activation of osteoclasts by RANKL. By blocking RANKL, denosumab inhibits osteoclast formation, function and survival, thereby decreasing bone resorption and increasing bone mass in postmenopausal women and patients with thalassaemia-induced osteoporosis.

Keywords

Thalassemia; Hemoglobinopathies.

Full Text:

PDF
Submitted: 2018-04-11 15:45:08
Published: 2018-04-19 10:14:19
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
149

Views:
PDF
26

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2018 Ersi Voskaridou, Maria Dimopoulou, Evangelos Terpos

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185     •     Privacy